Neurolmed
Manufacturing · South Korea · 11-50 Employees
View Company Info for Free
Overview
Headquarters
에이스광교타워 91 창룡대로256번길 2 302호, Suwon, Gyeo...Website
www.neurolmed.comRevenue
<$5 MillionIndustry
ZI Rank: 1
About Neurolmed
Neurolmed Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Neurolmed your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Neurolmed has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Funding: Get notified immidiatlly once Neurolmed has new funding data
Click to see if Neurolmed had a recent Job posting/layoffs
Product Launch: Get notified when Neurolmed launches new products
Congratulate Masked Content for being promoted to Masked Content at Neurolmed
Neurolmed, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Check out if Neurolmed is spiking on competitors!
Earning: See what the market has to say on Neurolmed recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined Neurolmed as Masked Content
Find more new buyers
Neurolmed Tech Stack
A closer look at the technologies used by Neurolmed
Top Manufacturing Companies
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Neurolmed
Neurolmed is a biopharmaceutical company based in South Korea, dedicated to developing drugs from biomolecules and natural products for the treatment of acute or chronic degenerative cerebral disorders, including stroke, Parkinson's, and Alzheimer's diseases. The company aims to fundamentally overcome various diseases by providing definitive cures... Read More
